The latest update is out from Summit Therapeutics ( (SMMT) ).
Summit Therapeutics is making significant strides in the development of ivonescimab, a promising bispecific antibody for non-small cell lung cancer (NSCLC). Recent Phase III trials in China showed ivonescimab reducing disease progression by 49% compared to pembrolizumab. With ongoing trials and FDA Fast Track Designation, Summit aims to expand its clinical reach in NSCLC and explore further applications in other solid tumors, backed by robust investment and promising early data.
For an in-depth examination of SMMT stock, go to TipRanks’ Stock Analysis page.
